Accelerating Therapeutic DiscoveryTM

News From The Alpha-1 Project

07

Scientific founders who originated the miRNA mediated “silence and replace” approach take on Alpha-1 and ALS

US patent awarded for its proprietary THRIVE™ platform

Appoints new Chief Technology Officer with rAAV gene therapy cGMP manufacturing and virology expertise

 

Apic Bio, Inc. an innovative gene therapy company developing best-in-class treatment options for patients with rare genetic diseases, today announced the completion of a $40 million Series A financing led by Morningside Venture. Existing investors, The Alpha-1 Project (TAP) and A1ATD Investors, LLC also participated along with new investor, the ALS Investment Fund.

[Read More...]

17
Based on the most recent data from the ADVANCE clinical trial, the Company is reviewing the learnings from the study, notably on the AAVrh.10 capsid in order to inform further development of gene therapy candidates for the treatment of rare diseases. The Company plans to conduct additional preclinical studies to determine the best gene therapy candidate to advance. The Company plans to provide an update on the rare disease programs in the first half of 2019 and will not submit an IND application for ADVM-053 for the treatment of hereditary angioedema (HAE) in the fourth quarter of 2018.

[Read More...]

06
London, UK and Redwood City, California, USA, 5 December 2018 – Mereo BioPharma Group plc (AIM: MPH) (“Mereo”, the “Company” or the “Group”), the clinical stage UK based biopharmaceutical company focused on rare diseases, and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED) (“OncoMed”), a NASDAQ listed oncology-focused clinical stage biopharmaceutical business, today announce the proposed combination of Mereo and OncoMed (the “Transaction”). The Transaction has been unanimously approved by the Board of Directors of each company.

[Read More...]

05

Investment from The Alpha-1 Project

Top line data expected H2 2019

London, 5 November 2018 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, is pleased to announce that the first patient has been dosed in its Phase 2 clinical study of MPH-966 (alvelestat) for the treatment of alpha-1 antitrypsin deficiency (AATD). The study is being conducted in the United States and Europe with top line data expected in H2 2019.

The Company also announced today a collaboration with and investment from the venture philanthropy arm of the Alpha-1 Foundation, The Alpha-1 Project, Inc. (TAP). TAP is investing in Mereo’s MPH-966 development programme subject to the Company meeting agreed development milestones. The Company has also agreed to issue warrants to TAP, on future dates, to subscribe for shares in the Company subject to TAP making the agreed investments in the programme with the first such investment milestone being the dosing of the first patient in the MPH-966 development programme.

[Read More...]

24
Summary: She has become one of the country’s leading advocates on patient-centered drug development and clinical trial design    The Alpha-1 Project (TAP) announces the appointment of Karen Erickson as Chief Operating Officer, a new...

[Read More...]

Page 1 of 4First   Previous   [1]  2  3  4  Next   Last